Polish Stem Cells Bank (PBKM)/ FamiCord Group

famicord.eu

The Polish Stem Cells Bank (PBKM) is operating on the international market under the brand of FamiCord Group, which was founded in 2002. It is a stem cell bank, engaged in the acquisition, processing and long-term storage of stem cells taken from umbilical cord blood and other fetal tissues on behalf of parents – family banking. The aim of PBKM is to ensure access of the family for stem cells in case of need for therapy. As of 2017 FamiCord has released more than 30 units of cord blood for transplantatation and more than 1000 units of stem cells from other sources. Currently Famicord Group operates directly in Poland, Spain, Turkey, Latvia, Hungary, Romania, Italy and through business partners in Sweden, Ukraine, Serbia and UK .

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GENETIC TESTING MARKET TO SET NEW GROWTH STORY: TRANSGENOMIC, GE HEALTHCARE, 23 & ME

EIN News | April 16, 2020

news image

Advance Market Analytics released the research report of Global Genetic Testing Market, offers a detailed overview of the factors influencing the global business scope. Global Genetic Testing Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Genetic Testing. This Report covers the emerging player’s data, including: competit...

Read More

GSK COLLABORATES WITH VIR BIOTECHNOLOGY TO FIND CORONAVIRUS SOLUTIONS

HospiMedica International | April 07, 2020

news image

GlaxoSmithKline plc (London, UK) and Vir Biotechnology, Inc. (San Francisco, CA, USA) have entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbr...

Read More

MEDGENOME TO INVESTMENT $55M LED BY LEAPFROG INVESTMENTS

Express Healthcare | April 02, 2020

news image

The investment in MedGenome will seek to capitalise on favourable dynamics in both domestic, international markets for genetic diagnostics. MedGenome recently announced an investment of $55m led by LeapFrog Investments. Existing investors Sofina and Sequoia also participated in the round. Sam Santhosh, CEO and Founder, MedGenome said, “Genomics and personalised medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India ...

Read More

COLLAPSE OF £550M DEAL TO SELL WOODFORD'S BIOTECHS SPARKS FIRE SALE FEARS

FierceBiotech | February 10, 2020

news image

A £550 million ($711 million) deal to find new homes for Neil Woodford’s biotech holdings has collapsed, raising the prospect that stakes in companies including Immunocore will be auctioned off for knock-down prices. Woodford became a go-to source of money for private British biotechs in the years after he left Invesco to set up his own fund. However, the illiquid nature of Woodford’s holdings in such companies became a problem as more and more investors began taking money out ...

Read More
news image

GENETIC TESTING MARKET TO SET NEW GROWTH STORY: TRANSGENOMIC, GE HEALTHCARE, 23 & ME

EIN News | April 16, 2020

Advance Market Analytics released the research report of Global Genetic Testing Market, offers a detailed overview of the factors influencing the global business scope. Global Genetic Testing Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Genetic Testing. This Report covers the emerging player’s data, including: competit...

Read More
news image

GSK COLLABORATES WITH VIR BIOTECHNOLOGY TO FIND CORONAVIRUS SOLUTIONS

HospiMedica International | April 07, 2020

GlaxoSmithKline plc (London, UK) and Vir Biotechnology, Inc. (San Francisco, CA, USA) have entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbr...

Read More
news image

MEDGENOME TO INVESTMENT $55M LED BY LEAPFROG INVESTMENTS

Express Healthcare | April 02, 2020

The investment in MedGenome will seek to capitalise on favourable dynamics in both domestic, international markets for genetic diagnostics. MedGenome recently announced an investment of $55m led by LeapFrog Investments. Existing investors Sofina and Sequoia also participated in the round. Sam Santhosh, CEO and Founder, MedGenome said, “Genomics and personalised medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India ...

Read More
news image

COLLAPSE OF £550M DEAL TO SELL WOODFORD'S BIOTECHS SPARKS FIRE SALE FEARS

FierceBiotech | February 10, 2020

A £550 million ($711 million) deal to find new homes for Neil Woodford’s biotech holdings has collapsed, raising the prospect that stakes in companies including Immunocore will be auctioned off for knock-down prices. Woodford became a go-to source of money for private British biotechs in the years after he left Invesco to set up his own fund. However, the illiquid nature of Woodford’s holdings in such companies became a problem as more and more investors began taking money out ...

Read More